If you have been reading about metabolic research and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-01-30. Numbers and descriptions here follow the published literature rather than marketing material.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; visual inspection |
| Solubility | Soluble in water and aqueous buffers | Depends on pH, purity, and counterion |
| Typical storage | -20 °C or below, desiccated | Protect from light; avoid repeated freeze-thaw after reconstitution |
| Common analytical method | Reversed-phase HPLC and mass spectrometry | Purity by HPLC; identity and mass by LC-MS or MALDI-TOF |
| Common synonyms | hGH fragment 176–191; AOD-9604 | Names vary in research and product labeling |
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
The Scottish Government loses a non-binding vote calling for the rollout of free school meals to all primary school pupils, with MSPs voting 64–2 for the motion. 13 September – Former nurse Adele Rennie is sentenced to two years and four months in prison and placed on the sex offenders' register for ten years after pleading guilty to stalking a woman online, while posing as a man, after the dating app Tinder matched them. 15 September – The A83 road in Argyll is reopened with a slight diversion after heavy rain caused a 500 tonne landslide. 17 September – Glasgow is formally selected as the host city of the Commonwealth Games in 2026. 18 September – Scotland experiences its warmest September day since 2019, with temperatures reaching 25 °C. 19 September – The Scottish Government temporarily pauses a ban on wood burning stoves in new properties and property conversions following a review of the legislation. Greenock Morton F.C. dismisses player Jay Emmanuel-Thomas after he appeared in court accused of attempting to orchestrate the smuggling of drugs into the UK. 20 September – A woman juror who used the Right Move app to research the floorplan of a house similar to one that was the scene of a rape during a trial is fined for contempt of court. 24 September – Official figures show the number of households living in temporary accommodation has reached a record high, with 16,300 households in the system as of March 2024, the highest since records began in 2002.
The Fascial Net Plastination Project (FNPP) is an anatomical research initiative led by fascia researcher Robert Schleip. The project aims to enhance the study of fascia through the technique of plastination. Led by an international team of fascia experts and anatomists, the FNPP resulted in the creation of a full-body fascia plastinate known as FR:EIA (Fascia Revealed: Educating Interconnected Anatomy). This plastinate provides a detailed view of the human fascial network, allowing for a better understanding of its structure and function as an interconnected tissue throughout the body. FR:EIA was unveiled at the 2021 Fascia Research Congress and is currently exhibited at the Body Worlds exhibition in Berlin. This project represents a significant contribution to the visualization of fascia and has the potential to influence future research in fields such as medicine, physical therapy, and movement science.
== Treatment == Treatment for AGAT and GAMT mainly consists of creatine supplementation. GAMT treatment may also include ornithine and sodium benzoate supplementation and/or diet restrictions in arginine and/or protein. These have shown to be effective, especially when started early in life. There is no current effective treatment for CTD. Creatine supplementation can have some benefit but because creatine does not easily pass the blood-brain barrier without a functioning transporter, neurological symptoms remain significant.
Sources: en.wikipedia.org
The Moderna COVID-19 vaccine, manufactured by Moderna since 2020, is a lipid nanoparticle (LNP) encapsulated mRNA-based vaccine that encodes for a full-length, prefusion stabilized spike(S)-2P antigen of SARS-CoV-2 with a transmembrane anchor.
The Sudetenland ( soo-DAY-tən-land, German: [zuˈdeːtn̩ˌlant]; Czech and Slovak: Sudety) is the historical German name for the northern, southern, and western areas of former Czechoslovakia which were inhabited primarily by Sudeten Germans. These German speakers had predominated in the border districts of Bohemia, Moravia, and Czech Silesia since the Middle Ages. The word Sudetenland did not come into being until the early part of the 20th century and did not come to prominence until almost two decades into the century, after World War I, when Austria-Hungary disintegrated and the Sudeten Germans found themselves living in the new country of Czechoslovakia. The Sudeten crisis of 1938 was provoked by the Pan-Germanist demands of Nazi Germany that the Sudetenland be annexed to them, which happened after the later Munich Agreement. Part of the borderland was invaded and annexed by Poland. Afterwards, the formerly unrecognized Sudetenland became an administrative division of Germany. When Czechoslovakia was reconstituted after World War II, the Sudeten Germans were expelled and the region today is inhabited almost exclusively by Czech speakers. The word Sudetenland is a German compound of Sudeten, the name of the Sudeten Mountains, which run along the northern Czech border and Lower Silesia (now in Poland), and Land, meaning "country". The Sudetenland encompassed areas well beyond those mountains, however. Parts of the now-Czech regions of Karlovy Vary, Liberec, Olomouc, Moravia-Silesia, South Moravia and Ústí nad Labem are within the former Sudetenland.
April 11: Law concerning the prostitution of minors (under 18 years old). June 6: Law allowing for the automatic conversion of legal separation into divorce after three years. November 15: Women become eligible to serve on labor tribunals (Conseils de prud'hommes). September 27, 1909: Law guaranteeing employment or job security for women after childbirth — employment contracts may be suspended for eight consecutive weeks. March 15, 1910: Law granting a special two-month leave, with full pay, to schoolteachers after childbirth — this corresponds to maternity leave. July 13, 1911: The two-month maternity leave granted to schoolteachers is extended to women employed by the postal, telegraph, and telephone services (PTT). 1912
Sources: en.wikipedia.org
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.
Mass spectrometry, such as LC-MS or MALDI-TOF, confirms the molecular mass and can reveal sequence-related impurities. Reversed-phase HPLC is used for purity, and peptide mapping or amino acid analysis can support sequence identity. No single method establishes every quality attribute.
No. AOD9604 is a short synthetic fragment of the hGH sequence, not the full 191-amino-acid hormone. It lacks the regions that mediate hGH receptor activation and growth-promoting effects. Products labeled as AOD9604 should not be assumed to have the same properties as hGH.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.